Abby Hardy, Author at BioTuesdays

Developments

AC Immune initiates second dosing group in Phase 1b/2a Alzheimer’s disease vaccine trial

AC Immune (NASDAQ:ACIU) initiated the second highest dosing group in a Phase 1b/2a clinical trial evaluating its anti-phospho-tau vaccine in patients with early Alzheimer’s disease (AD). The vaccine, called ACI-35...

July 16, 2020

Developments

Imagin Medical to test i/Blue Imaging System on anatomical bladder models

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) will use anatomical bladder models to confirm the i/Blue Imaging System’s simultaneous white and blue light image display. The anatomical...

July 15, 2020

Executive Moves

Neuronetics names Keith Sullivan as president and CEO

Keith Sullivan Neuronetics (NASDQ:STIM) appointed Keith Sullivan as president and CEO, effective immediately. Christopher Thatcher, the company’s previous president and CEO, resigned in March 2020. Mr. Sullivan has more...

July 14, 2020

Developments

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Rigel Pharmaceuticals’ (NASDAQ:RIGL) fostamatinib is being evaluated in an investigator-sponsored study for the treatment of COVID-19 pneumonia. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is approved...

July 14, 2020

Developments

Histogen completes enrollment in Phase 1b/2a alopecia trial

Histogen (NASDAQ:HSTO) completed patient enrollment in its Phase 1b/2a clinical trial evaluating HST 001 for the treatment of androgenic alopecia in men. The trial enrolled 36 subjects with male pattern hair loss who...

July 14, 2020

Developments

Verrica Pharma gets complete response letter for molluscum contagiosum drug

The FDA issued Verrica Pharmaceuticals (NASDAQ:VRCA) a complete response letter (CRL) regarding the company’s NDA for VP-102. VP-102 is a topical cantharidin solution designed to treat molluscum contagiosum, a viral...

July 14, 2020

Developments

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

Akebia Therapeutics’ (NASDAQ:AKBA) vadadustat is being evaluated in an investigator-sponsored study as a potential therapy to prevent and lessen the severity of COVID-19-related acute respiratory distress syndrome...

July 14, 2020

Developments

Albireo Pharma enrolls first patient in Phase 3 biliary atresia trial

Albireo Pharma (NASDAQ:ALBO) enrolled the first patient in its Phase 3 BOLD clinical trial of odevixibat for the treatment of biliary atresia. Odevixibat is an inhibitor of the ileal bile acid transporter and is...

July 14, 2020

Feature

NeuroOne developing electrode technology to treat neurological conditions

NeuroOne (OTCQB:NMTC) is developing high-definition, minimally invasive thin-film electrodes for the diagnosis and treatment of various neurological conditions, including epilepsy, Parkinson’s disease (PD) and chronic...

July 14, 2020

Developments

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), began enrolling patients in its Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is an orally...

July 13, 2020

Author - Abby Hardy

AC Immune initiates second dosing group in Phase 1b/2a Alzheimer’s disease vaccine trial

Imagin Medical to test i/Blue Imaging System on anatomical bladder models

Neuronetics names Keith Sullivan as president and CEO

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Histogen completes enrollment in Phase 1b/2a alopecia trial

Verrica Pharma gets complete response letter for molluscum contagiosum drug

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

Albireo Pharma enrolls first patient in Phase 3 biliary atresia trial

NeuroOne developing electrode technology to treat neurological conditions

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

General

More